Trial Profile

A Randomized Double-Blind, Placebo-Controlled Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SEL 212 (Primary)
Indications Gout
Focus Registrational; Therapeutic Use
Acronyms DISSOLVE II
Sponsors Selecta Biosciences

Most Recent Events

25 Oct 2025 According to Sobi North America media release, data from this trial presented at the annual American College of Rheumatology (ACR) Convergence 2025 meeting
25 Oct 2025 Results published in the Sobi North America Media Release
24 Oct 2025 According to a Swedish Orphan Biovitrum media release, data from this trial will be presented at the annual American College of Rheumatology (ACR) Convergence 2025 meeting in Chicago, October 24-29.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com